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ABSTRACT
The largest subunit of RNA polymerase II shows a
striking difference in the degree of phosphorylation,
depending on its functional state: initiating and elong-
ating polymerases are unphosphorylated and highly
phosphorylated respectively. Phosphorylation mostly
occurs at the C-terminal domain (CTD), which consists
of a repetitive heptapeptide structure. Using the yeast
two-hybrid system, we have selected for mammalian
proteins that interact with the phosphorylated CTD of
mammalian RNA polymerase II. A prominent isolate,
designated SRcyp/CASP10, specifically interacts with
the CTD not only in vivo but also in vitro. It contains a
serine/arginine-rich (SR) domain, similar to that found
in the SR protein family of pre-mRNA splicing factors,
which is required for interaction with the CTD. Most
remarkably, the N-terminal region of SRcyp includes a
peptidyl-prolyl cis-trans isomerase domain character-
istic of immunophilins/cyclophilins (Cyp), a protein
family implicated in protein folding, assembly and
transport. SRcyp is a nuclear protein with a character-
istic distribution in large irregularly shaped nuclear
speckles and co-localizes perfectly with the SR domain-
containing splicing factor SC35. Recent independent
investigations have provided complementary data,
such as an association of the phosphorylated form of
RNA polymerase II with the nuclear speckles, impaired
splicing in a CTD deletion background and inhibition of
in vitro splicing by CTD peptides. Taken together, these
data indicate that factors directly or indirectly involved
in splicing are associated with the elongating RNA
polymerases, from where they might translocate to the
nascent transcripts to ensure efficient splicing,
concomitant with transcription.
INTRODUCTION
The C-terminal domain (CTD) of the largest subunit of RNA
polymerase II (pol II) consists of tandem repeats of a heptapeptide
motif with the consensus sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser.
The CTD is highly conserved among different species (1,2) and
is essential for in vivo functions (3–6). The phosphorylation status
of the CTD appears to be regulated throughout the transcription
cycle. There is good in vivo evidence that the CTD of the
elongating form of pol II is hyperphosphorylated (pol IIO) (7),
while pol II that is associated with the pre-initiation complex is
essentially unphosphorylated (pol IIA) (8,9). Multiple intermedi-
ate forms between pol IIA and pol IIO exist and the CTD could
be involved in different pre- and post-initiation functions.
The basal transcription factors TBP and TFIIE interact with the
unphosphorylated form of the CTD directly (10,11). Phospho-
rylation by TFIIH-associated CTD kinase might disrupt such
interactions and thereby promote initiation and elongation of
transcription (12). Recent evidence indicates that a transcription-
ally active form of pol II exists as a holoenzyme, composed of
core pol II, a large multiprotein complex termed the mediator or
SRB complex (suppressors of RNA polymerase B) which
interacts with the CTD and possibly some additional components,
including general transcription factors and components of the
SWI–SNF complex (13,14), in line with the demonstrated
importance of the CTD for regulated transcription (15). An active
pol II holoenzyme complex has been isolated from mammalian
cells (16,17) and was reported to contain essentially the pol IIA
form (16).
The CTD has been proposed as a binding site for splicing
factors (18). Splicing is thought to occur, at least in part,
co-transcriptionally: spliceosomes have been visualized at active
sites of transcription on spread chromatin (19–21) and there is
evidence for splicing of nascent mRNAs that are still associated
with chromatin (22,23). Accordingly, several gene loci were
shown to coincide with their specific nascent and spliced
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transcripts (24–26). Components of the transcription and splicing
machineries form a fine fibrogranular reticulum that connects
20–50 larger domains, the so-called nuclear speckles (20,26). The
nuclear speckles are retained in nuclear matrix preparations
(27,28) and are rich in splicing factors, such as members of the
serine/arginine-rich (SR) family (28–30). Most pre-mRNA syn-
thesis occurs in defined foci which are distinct from the nuclear
speckles, at sites corresponding to the previously described
perichromatin fibrils (21,31,32). This finding is consistent with the
idea that the speckles could be a site for storage and assembly of
splicing factors (29). However, transcription and splicing of
several genes were found to be in close spatial association with the
nuclear speckles, indicating that these structures might also have a
functional role in mRNA processing (24).
Intron-containing reporter genes under the control of a pol III
promoter are not spliced, suggesting that splicing could be
dependent on transcription by pol II (33). Pol IIO was detected in
the nuclear speckles and could be co-immunoprecipitated with
splicing factors (34–36). Consistent with these data, several SR
proteins have been isolated that interact with the CTD (37). It has
recently been demonstrated that a set of 3′-processing factors also
interact with the CTD directly and that deletion of the CTD affects
both RNA splicing and 3′-processing in vivo (38).
We screened a human cDNA library for proteins interacting
with the CTD of mammalian pol II using the yeast two-hybrid
system. We isolated a nuclear matrix protein, SRcyp, containing
an SR domain that is distinct from the CTD binding proteins
previously described (37). According to a nomanclature to be
proposed by Jeffry Corden (Johns Hopkins University, personal
communication) for all published and unpublished CTD-
associated SR-like proteins isolated by different laboratories so
far, our SRcyp would be CASP10. SRcyp/CASP10 is found in the
nuclear speckles, suggesting that it could be a component of
splicing factor complexes that bind the CTD, thereby linking
RNA processing to transcription.
MATERIALS AND METHODS
Plasmids
The XhoI–XbaI fragment from the following GAL4 (1–93) fusion
constructs, GAL4–CTD52x (39), GAL4–nuc(170–277) and
GAL4–cbl2(352–469) (40), were transferred into pGG25∆X (41).
The yeast expression cassette was transferred as a BamHI fragment
into pRS314 (42) to generate pRS314-CTD, pRS314-nuc(170–277)
and pRS314-cbl2(352–469). SRcyp mutants were generated by
PCR and cloning in pGAD424 (Clontech). c24 was transferred as
a BglII fragment into the BamHI site of pGAD424. SRcyp was
cloned in pCATCH*, a variant of pCATCH (43). SRcyp was
reconstructed by insertion of the fragments NcoI–BglII and
BglII–XhoI from two overlapping cDNAs into the pCATCH*
EcoRV and XhoI sites. In pCATCHV the FLAG epitope is replaced
by an 11mer VSV epitope from vesicular stomatitis virus G protein
(44), by inserting the following annealed oligonucleotides into the
HindIII and BamHI sites of pCATCH: 5′-AGCTCGGTAC-
CGAGCGGATCACCACCATGTATACAGACATAGAGATGA-
AACCG-ACTTGGAAAGGGAAGCTTACG-3′ and 5′-GATCC-
GTAAGCTTCCCTTTCCAAGTCGGTTCATCTCTATGTCT-
GTATACATGGTGGTGATCCGAGCTCGGTACCG-3′.
Yeast two-hybrid screen
The GAL–CTD fusion construct did not activate transcription in
the yeast strain Y153 and was used to screen a human peripheral
blood lymphocyte cDNA library tagged to the GAL4 activation
domain in pACT as described (45), testing 2 × 106 transformants
for histidine prototrophy and positive β-galactosidase staining on
selective drop-out medium containing 25 mM 3-aminotriazole
(Sigma). The insert junctions of 36 positive clones were
sequenced. The interactions of positive clones with unrelated
baits and of SRcyp mutants with GAL–CTD were tested under
the same conditions for at least three independent colonies.
Full-length cloning
The λACT cDNA library (45) and a λGT10 cDNA library from
BJA-B cells were screened with two random primed fragments from
SRcyp. The inserts were sequenced on both strands using specific
primers and nested deletions (Pharmacia nested deletion kit).
Dephosphorylation of the yeast extracts
Samples of 10 µg total yeast extract (46) were diluted to a volume
of 100 µl with 100 mM Tris–HCl, pH 9.6, 2 mM MgCl2, 0.1 mM
ZnCl2 and treated with different concentrations of calf intestinal
phosphatase (NEB) for 10 min at room temperature in the absence
or presence of phosphatase inhibitors (5 mM sodium fluoride, 5 mM
sodium vanadate, 5 mM EDTA and 5 mM EGTA). GAL–CTD
was detected by immunoblotting with the anti-CTD monoclonal
antibodies (mAbs) H5 and H14 and polyclonal anti-PRP20
antibody. Detection was by ECL (Amersham).
GST protein production and precipitation
A GST fusion protein to a positive clone (c24) and GST alone
were produced and bound to gluthatione–CL4B Sepharose
(Pharmacia) according to the manufacturer’s recommendations
(lysis buffer, 10 mM Tris, pH 8.0, 500 mM NaCl, 10% glycerol,
0.1% Tween 20 supplemented with 1 mM PMSF). The resin was
washed four times with 1 ml lysis buffer and twice with 1 ml
binding buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 5 mM EDTA,
0.25% NP40, 1 mM sodium fluoride, 1 mM sodium vanadate,
1 mM PMSF). For precipitations, 20 µl bed volumes of GST
fusion protein-bound resin were mixed with 300 µg yeast whole
cell extract prepared from Y153 containing pRS314-GAL(1–93)
or pRS314-CTD in a final volume of 200 µl binding buffer and
incubated overnight on a rotator at 4C. The resin was washed five
times with binding buffer and the proteins were eluted by boiling
in SDS–PAGE sample buffer. Immunoblotting was as above.
Immunofluorescence assay
Transfected HeLa cells were grown on 14 mm glass coverslips.
Inhibition of pol II was with α-amanitin (50 µg/ml) for 8 h as
described (47). Fixation was with 1.75% paraformaldehyde for
15 min and permeabilization with 0.5% Triton X-100 in
phosphate-buffered saline for 2.5 min at room temperature. Cells
were labelled with 3 µg/ml anti-FLAG M2 (Eastman Kodak),
rabbit polyclonal antiserum 49 anti-VSV 1:500 and anti-SC35
(48) 1:4, using standard techniques and mounted in Mowiol.
Nuclear matrix preparations were extracted with Triton X-100,
DNase I (1000 U/ml; Boehringer Mannheim) and ammonium
sulphate according to the literature (47,49). Cells were viewed on
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a Leica TCS Confocal Laser Scanning Microscope (Leica,
Heidelberg). The digitized micrographs were merged with Imaris
software (Bitplane, Zurich).
RESULTS
Two-hybrid screen with the mammalian CTD
A fusion of the CTD of mouse pol II (52 repeats) to the GAL4
DNA binding domain (amino acid residues 1–93) (39) was used
to screen a human peripheral blood lymphocyte cDNA library
fused to the GAL4 activation domain in yeast strain Y153 (45).
The specificity of the interaction of the positive CTD interacting
clones was verified by transforming the isolated clones in Y153
strains expressing either GAL–CTD (pRS314-CTD), GAL DNA
binding domain [pRS314-GAL(1–93)] or a fusion with acidic
regions of the cytoplasmic oncogene cbl [pRS314-cbl2(352–469)]
and of nucleolin [pRS314-nuc(170–277)], which are highly acidic
and do not activate transcription (40). Reporter gene activation by
the positive clones was strictly dependent on the presence of the
CTD and the positive clones did not interact with the GAL4 DNA
binding domain alone or the GAL4 DNA binding domain fused to
highly charged portions of unrelated proteins. The GAL4
activation domain alone activated the reporter genes when
co-transformed with GAL–CTD (data not shown). Expression
levels of the GAL4 fusion constructs in yeast strain Y153 were
compared by electrophoretic mobility shift assays and found to be
similar in the four strains (data not shown). Sequencing of the
cDNA inserts revealed multiple overlapping clones of four
different types of cDNAs (see Discussion).
A serine/arginine-rich CTD binding protein
We focused on a family of three overlapping cDNA clones which
contain a region of homology with SR domains of RNA splicing
factors (Fig. 2, clones c19, c24 and c26). The full-length cDNA,
isolated from a human B-lymphocyte cDNA library, spans 2695
nt and contains an open reading frame of 754 amino acids
(Fig. 1A and B). Translational stops are found in all three frames
upstream of the first AUG and the length of the cDNA is
consistent with a single band of ∼3.0 kb in Northern blots. The
SRcyp gene is expressed in all cell types we have tested to date
(data not shown).
A 177 amino acid stretch in the N-terminal portion has a high
identity to the cyclophilin-type peptidyl-prolyl cis-trans isomer-
ases (PPIase), while the remainder of the protein is highly
charged. An acidic serine-rich region flanked by stretches of basic
residues is adjacent to the N-terminal PPIase and an SR domain
is found in the C-terminal portion of SRcyp (Fig. 1A). The region
from amino acid 540 to 639 contains 14% serine, 29% arginine,
13% SR dipeptides and 12% RS dipeptides (underlined and in
bold in Fig. 1B). Shorter stretches of SR repeats are found outside
the SR homology region. The SR domains of SRcyp, of the CTD
binding proteins isolated by the group of J.Corden (37) and of two
further serine/arginine-rich CTD binding proteins isolated in our
screen all have a similar serine, arginine and SR/RS peptide
content (S.Tanner, J.P.Bourquin and W.Schaffner, unpublished
results). These sequence features suggest that these proteins are
related to the SR protein family of splicing factors. From position
180 to 754 of SRcyp, 71.3% of the residues are Glu, Asp, Lys,
Arg, Ser or Thr and positively and negatively charged residues
Figure 1. Sequence analysis of human SRcyp. (A) Schematic drawing of the
domains of SRcyp. PPIase, peptidyl-prolyl cis/trans isomerase; alternating +/–,
alternating charged amino acids. (B) Conceptual translation of the full-length
cDNA. Amino acids are numbered on the right. (C) Comparison of the PPIase
domains of SRcyp, NK-TR1, Bmcyp, C.elegans protein CEESF41R (Cecyp),
RanBP2 and human cyclophilin A (CypA). The gaps introduced to maximize
the homology are represented by dots. Identical amino acid positions are shaded
in black, conservative changes in grey. The conserved amino acid residues in
the cyclosporin A binding pockets are indicated by numbers below the
sequence alignment. Sequence alignments were performed using PILEUP
(GCG, Wisconsin) and edited with BOXSHADE.
alternate regularly. Additional negative charges might be intro-
duced by phosphorylation on serine and threonine residues. Such
an alternation of positive and negative charges has been proposed
to be a sequence feature of splicing factors (50).
SRcyp is related to a group of large cyclophilins
With 37.8% amino acid identity (71% within the cyclophilin-like
domain, Fig. 1C), SRcyp appears to be most closely related to
NK-TR1, which is a myeloid-specific nuclear protein containing
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Figure 2. Mapping of the CTD interaction domain of SRcyp with SRcyp
mutants in a GAL–CTD two-hybrid assay. The sequence boundaries of the
clones isolated in the yeast screen (c19, c24 and c26) and the deletion mutants
are shown with the corresponding amino acid positions indicated on the right.
The qualitative intensity of the β-galactosidase staining, detected in a filter test
for three independent colonies, is indicated: +++, an intense blue staining
appearing within 1 h; +/–, a pale blue signal observed after several hours.
three SR domains. NK-TR1 has PPIase, protein folding and
chaperone activities and is important for myeloid cell
differentiation and cytotoxic function of natural killer cells (51,52).
Similar sequence motifs are present in Bmcyp from Brugia malayi,
a filarial nematode (53), and a putative protein from
Caenorhabditis elegans, encoded by the cDNA CEESF41R. All
four cyclophilin-like proteins are highly charged outside the PPIase
motif and share regions enriched for serine, arginine and lysine
residues and a serine-rich stretch. Their PPIase domains differ from
other cyclophilins by an eight amino acid insertion (position 52 of
the SRcyp sequence) and a substitution of a histidine for the
conserved tryptophan residue in the cyclosporin A binding site
(indicated by * in Fig. 1C; 53). The Trp→His substitution is also
found in the PPIase domain of RanBP2, a large nucleopore protein
that has chaperone activity involving proline isomerization (54).
The occurrence of a serine/acidic-rich stretch alternating with
blocks of basic residues (180–253) resembles sequence motifs
found in nuclear localization signal binding proteins (55). From
these findings it is evident that SRcyp is related to a conserved
family of large cyclophilin-like proteins.
The SR domain is required for the interaction of SRcyp
with the CTD
SR domains have been implicated in protein–protein interactions
(30,56). Since all the SRcyp fragments isolated in the two-hybrid
screen contained the SR domain, we tested whether this domain
was required for binding to CTD. A series of SRcyp deletion
mutants was tested for CTD interaction in the two-hybrid assay
(Fig. 2). An SRcyp fragment containing amino acids 520–667 is
sufficient for an interaction which is comparable in strength to
that observed with the full-length protein. An N-terminal deletion
up to position 550 abolished the interaction with the CTD
completely, while a SRcyp fragment starting at position 544 still
retained the ability to interact with the CTD. We conclude that the
interaction domain is contained within amino acids 544–667.
This portion of SRcyp includes the SR domain (540–639), as
defined by sequence comparison. We also tested if SRcyp
required the full-length CTD for interaction. We found significant
but weaker interaction with the proximal conserved 22 heptapep-
tide repeats of the CTD and with the 26 repeats of the yeast CTD
(a kind gift of R.Young, MIT, Cambridge, MA; data not shown).
The mammalian CTD fused to the GAL4 DNA binding
domain is phosphorylated in yeast
To investigate the phosphorylation state of the CTD in the context
of the GAL4 DNA binding domain fusion, we took advantage of
two antibodies that recognize different phosphoepitopes on the
CTD (34). mAb H5 recognizes the 240 kDa Pol IIO form, while
mAb H14 binds multiple intermediate phosphorylation forms
between 220 and 240 kDa. Yeast whole cell extracts from Y153
strains expressing GAL–CTD were analysed by immunoblotting
with mAb H5 and H14. Both mAbs detected a specific band of
apparent size 70 kDa in extracts from strains expressing
GAL–CTD. As described previously (34), this signal depends on
the presence of phosphoepitopes on the CTD, because treatment
of the extracts with calf intestinal phosphatase resulted in its
dose-dependent reduction (Fig. 3). Complete loss of the signal
was observed when using a longer incubation time with
phosphatase and similar results were obtained using phage λ
protein phosphatase (data not shown). The signal was not affected
when phosphatase inhibitors were added to the reaction or in the
absence of phosphatase, confirming that this effect is due to
dephosphorylation. Unexpectedly, we did not observe an increase
in mobility of the GAL–CTD fusion protein with dephosphoryla-
tion, although this is consistent with an earlier observation
describing the effect of increasing CTD phosphorylation in vitro
as an initial retardation followed by an increase in electrophoretic
mobility on SDS–polyacrylamide gels (57). Taken together, these
results imply that a significant amount of the GAL–CTD
construct is phosphorylated in strain Y153 under the selective
conditions used in the screen. However, we cannot exclude the
possibility that a fraction of the GAL–CTD fusion is not
phosphorylated. A single band of ∼210 kD is recognized by both
H5 and H14 and most likely represents the large subunit of yeast
pol II, which is consistent with previous observations (58). The
H5 signal disappears before the H14 signal with dephosphoryla-
tion, which is consistent with earlier observations with pol II
using these antibodies (34).
The CTD interacts with SRcyp in vitro
A portion of SRcyp corresponding to a positive clone (c24) was
expressed as a GST fusion protein, immobilized on gluthatione–
Sepharose beads and the binding of GAL–CTD from yeast
extracts was tested. A significant proportion of GAL–CTD was
retained by GST–c24 (Fig. 4, lane 3), but not by GST alone
(lane 5), indicating that the CTD interacts with c24 directly.
Monoclonal antibodies (H5 and H14) that recognize CTD
phosphoepitopes on the hyperphosphorylated form of pol II (36)
detected the GAL–CTD fusion used here. While the antibodies
preferentially detect the phosphorylated form of pol II, we cannot
exclude the possibility that a fraction of unphosphorylated CTD
interacts with GST–c24 in this assay
.
SRcyp is a nuclear matrix-associated protein and
co-localizes with RNA splicing factors at nuclear speckles
Transient transfections in HeLa cells and COS cells with SRcyp
tagged either with the 8mer FLAG or the 11mer VSV epitope and
subsequent immunostaining revealed a nuclear localization with a
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Figure 3. The mammalian CTD fused to the GAL4 DNA binding domain is
phosphorylated in yeast. Yeast whole extracts from Y153 strains with or
without the GAL–CTD expression vector were incubated with the indicated
calf intestinal phosphatase (CIP) concentrations (in units) in the presence or
absence of phosphatase inhibitors. After separation on a 7% SDS–polyacryl-
amide gel, the proteins were immunoblotted using the monoclonal antibodies
H5 and H14 directed against different phosphoepitopes on the CTD as
indicated. Absence of significant proteolytic degradation of the samples was
monitored by visualizing the yeast PRP20p protein with a polyclonal antiserum.
The expected 54 and 52 kDa bands have similar intensities in all lanes. The
200 kDa band with mAbs H5 and H14 corresponds to the expected size of the
yeast pol II largest subunit. Lane 1, Y153 whole cell extracts; lanes 2–6, whole
cell extracts of Y153 expressing Gal–CTD. Molecular mass markers in kDa are
indicated on the left.
characteristic subnuclear distribution in speckles and an associated
fine reticular nucleoplasmic staining (Fig. 5a and b). SRcyp was
also detected in nuclear matrix preparations, which is expected for
a component of the nuclear speckles (Fig. 5c and d). The nuclear
distribution of SC35, a well-characterized pre-mRNA splicing
factor of the SR family (48), is often used to define the nuclear
speckles compartment. We used the VSV-tagged SRcyp construct
in double staining experiments with anti-SC35 and an anti-VSV
rabbit polyclonal antisera. Representative nuclei visualized by
confocal laser scanning microscopy are depicted in Figure 5e–j.
SRcyp co-localizes with SC35 at the nuclear speckles (Fig. 5e–g).
Due to the faint background staining with anti-VSV, we cannot be
sure that the weaker staining pattern outside the speckles entirely
coincides with the SC35 distribution. Upon inhibition of RNA
transcription or RNA splicing, the SC35-labelled speckles are
known to undergo a redistribution from irregularly shaped
interconnected speckles to enlarged round unconnected structures
(47,59). We found a similar redistribution of SRcyp when pol II
transcription was inhibited by α-amanitin and this pattern fully
overlapped with the enlarged rounded SC35 speckles (Fig. 5h–j).
Similar results were obtained with COS cells and in double
labelling with mAb Y12, an anti-Sm antibody that recognizes a
common epitope on different spliceosomal proteins (data not
shown). These results suggest that SRcyp is involved in some
aspects of RNA processing, possibly by linking a post-transcrip-
tional mechanism to transcription by pol II.
DISCUSSION
Using the two-hybrid system, we have isolated a serine/arginine-
rich protein that interacts with the CTD of pol II. SR domains are
found mostly in pre-mRNA splicing factors (30). SRcyp is
Figure 4. CTD binds to SRcyp in vitro. Yeast whole cell extract from Y153
expressing GAL4–CTD or GAL4(1–93) was incubated with GST or with GST
fused to c24 (SRcyp amino acids 520–730) purified on glutathione–CL4B
resin. After five washes proteins were eluted by boiling in sample buffer,
separated on a 12% SDS–polyacrylamide gel and analysed by immunoblotting
with the mAbs H5 and H14 as indicated. Aliquots of 10 µg yeast extract were
loaded as input control. Lane 1, GAL4–CTD; lane 2, GAL4(1–93). GST–c24
was mixed with GAL4–CTD (lane 3) or with GAL4(1–93) (lane 4). GST alone
was mixed with GAL4–CTD (lane 5) or with GAL4(1–93) (lane 6). CTD is
retained only by GST–c24 (lane 3). Molecular mass markers in kDa are
indicated on the left.
associated with the nuclear matrix and co-localizes with splicing
factors at the nuclear speckles, a nuclear compartment rich in
splicing factors. A form of the CTD that is detected by an
antibody specific for phosphoepitopes on pol IIO binds to SRcyp
in vitro. The presence of a PPIase domain in SRcyp suggests that
this protein could affect protein folding and the CTD with its high
proline content suggests itself as a target. These findings indicate
that SRcyp could facilitate formation of macromolecular com-
plexes linking elongating pol II to the splicing machinery.
The other proteins isolated in our two-hybrid screen contain
sequence features that are mostly found in RNA processing
molecules. One contains an RNA recognition motif and a region
rich in glutamic acid/arginine repeats, similar to a motif described
in pre-mRNA splicing factors (50), which is functionally
involved in RNA splicing. The other two contain a CTD binding
region that is very similar to that described for rA1 and rA9, two
SR proteins isolated by virtue of their CTD interaction (37). One
of our clones could be a homologue of rA9 (80% identity over the
cloned region), whereas the second is a large SR protein that is
clearly distinct from rA1 and rA9 outside the conserved CTD
binding region (69).
SR proteins form an expanding family of pre-mRNA splicing
factors that are thought to be involved in early splicing events
such as splice site selection and early spliceosomal assembly (30).
SR domains are necessary for specific interactions between
different SR proteins (56). We have shown that the SR domain of
SRcyp is required for the interaction with the CTD. A two-hybrid
screen with Clk/Sty, a protein kinase, identified several SR
proteins as specific substrates (60), among which was a clone
identical to our SRcyp (61). None of the six other SR proteins
described (60) that bind Clk/Sty interact with the CTD in our
assay (data not shown). Thus interaction of the CTD with SRcyp
cannot simply be explained by the high frequency of positive
charges in the SR domain, but clearly requires a specific
sequence. In addition, the other SR CTD binding proteins that we
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Figure 5. Nuclear localization of SRcyp and its co-localization with the splicing factor SC35. Transfected HeLa cells were stained by indirect immunofluorescence
using the mAb M2 against the FLAG epitope (anti-FLAG, FLAG epitope on SRcyp) (b and d), a polyclonal rabbit antiserum against the VSV epitope (anti-VSV, VSV
epitope on SRcyp) (e and h) and an anti-SC35 mAb (anti-SC35) (f and i). The superimposition of the two signals is shown in (g) and (j), where the alignment of green
and red signals appears yellow. The effect of transcriptional inhibition by α-amanitin is shown in panels (h)–(j). (a), (b) and (e)–(j), normal fixation procedure, (c) and
(d), nuclear matrix preparation. For comparison, differential interference contrast images are shown in (a) and (c). (a), (b), (c) and (d), 40×; (e)–(j), 100×.
and others have isolated do not interact with the CTD through
their SR domains, but rather through either of two other types of
conserved protein domains (37,69). Thus, the earlier speculation
that splicing factors of the SR protein family would interact with
the CTD through their SR domains (18) has not proven  generally
valid. Instead, SR-like proteins seem to bind to the CTD either via
the SR domain or via another domain, which probably allows for
an intricate network of interactions.
SRcyp is a nuclear matrix component. The nuclear matrix is a
fibrogranular network in the interchromatin space that consists
mainly of RNA and RNA processing factors and is thought to
form the structural basis for coupled transcription and RNA
processing (27,62). Recent studies identified subsets of large
SR-related proteins in the nuclear matrix that are possibly
involved in splicing (50,63,64). Epitope-tagged SRcyp has an
apparent molecular mass of ∼110 kDa, which is within the size
ranges of these large SR-related proteins. SRcyp shows the same
subnuclear distribution as the splicing factor SC35 and the
speckled pattern is affected by inhibition of pol II by α-amanitin,
as described previously (47). This identifies SRcyp as a
component of the nuclear speckles. The function of this nuclear
compartment, which contains most of the splicing factors, is still
controversial. Speckles are thought to represent a dynamic
structure with potential functions in storage, assembly and
recycling of RNA processing components (29). Most of the
newly synthesized RNA is, however, found in defined foci
outside and at the periphery of SC35 domains (21,31,32), which
occur in close spatial association with the nuclear speckles (26).
Consistent with the finding of Wansink et al. (31), we observed
that certain sites of pol II transcription coincide with the weaker
SRcyp staining, outside the speckles (data not shown). Recently,
a rat homologue of SRcyp (93% identity) that localizes to the
nuclear speckles has also been cloned. This protein co-immuno-
precipitates with other SR proteins and exhibits PPIase activity in
vitro (M.Mortillaro and R.Berezny, personal communication).
Increasing evidence supports the idea that the CTD is a binding
site for RNA processing factors: several SR proteins specifically
interact with the CTD (37,69). The hyperphosphorylated form of
pol II can be co-immunoprecipitated with monoclonal antibodies
against different splicing factors, suggesting that a complex of
splicing factors is associated with the CTD in vivo (35,36,65).
Recently it was shown that the 3′-processing factors CstF and
CPSF also specifically interact with the CTD. Accordingly, a
complete truncation of the CTD results in a significant decrease
in mRNA splicing and 3′-processing in vivo (38). Similarly,
overexpression of the 52 heptapeptide repeats of the CTD
interferes with RNA splicing in vivo (66). These results confirm
the previous observation of inhibition of an in vitro splicing
reaction with CTD peptides (37). Thus, the CTD could be crucial
for the formation of larger complexes of RNA processing factors
on elongating pol II and could play a central role in the coupling
of RNA processing to transcription. The assembly of such
complexes could be modulated by changes in the CTD phospho-
rylation status and/or in its conformation. Peptidyl-prolyl iso-
merization affects the local conformation of polypeptides (67)
and might therefore provide a regulatory mechanism to modify
the conformation of the CTD, which has a repetitive proline-rich
amino acid sequence. Alternatively, the formation of specific
protein complexes on the CTD might require some associated
nuclear chaperone functions. Chaperone activity of a cyclophilin,
Cyp40, has recently been demonstrated (68). Specific chaperones
could be involved in maintaining the CTD in a certain folded state
that could favour particular protein–protein interactions. As
mentioned before, SRcyp specifically interacts with Clk/Sty (61),
an SR protein kinase member of a family of protein kinases
involved in regulation of RNA splicing (56,60). This finding
raises the question of whether phosphorylation of SRcyp by
Clk/Sty could affect the interaction of pol II with the CTD, as part
of a regulatory mechanism of early splicing events. Further
experiments will have to address the question of whether the CTD
is a specific substrate for the PPIase activity of SRcyp and to what
extent this nuclear cyclophilin influences transcription and RNA
processing in vivo.
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